Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "Male"

Clinical trialCLINICALTRIALSToday

Trial Now Recruiting: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)

Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.

WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
You can act on thisnon-small cell lung cancerlocally advanced non-small cell lung cancermetastatic non-small cell lung cancerRead →
ResearchPUBMEDApr 13

Rare and uncommon tumours of the female pelvis: what the radiologist should know.

This article helps doctors who read medical images understand rare tumors that grow in women's reproductive organs. These tumors are uncommon, affecting fewer than 6 out of every 100,000 people each year, which makes them hard to diagnose and treat. The article explains what these tumors look like on imaging scans and how doctors can better identify them to help plan treatment.

WHY IT MATTERSIf you have been diagnosed with an uncommon gynecological tumor, radiologists who understand these rare conditions are better equipped to provide accurate imaging reports that guide your treatment decisions.
Good to knowRead →
Clinical trialUNITERAREApr 3

New Recruiting Trial: Androgenic Alopecia TH07 Clinical Trial

Triple Hair Inc is recruiting patients for a Phase 3 clinical trial testing a new treatment called TH07 for androgenic alopecia, commonly known as male or female pattern baldness. This is a large-scale study to confirm whether TH07 works better than current treatments. If you have pattern hair loss, you may be eligible to join and help test this potential new therapy.

WHY IT MATTERSThis Phase 3 trial is actively recruiting now, meaning if you have androgenic alopecia, you could potentially enroll and access an investigational treatment while contributing to evidence that could lead to FDA approval.
You can act on thisandrogenic alopeciaRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases